Report on the “Financial Empowerment for High‑Quality Development of Biomedical Enterprises in the Greater Bay Area” Conference

On May 21, the conference “Financial Empowerment for High‑Quality Development of Biomedical Enterprises in the Greater Bay Area” was successfully held at the Hampton by Hilton Guangzhou Tianhe Pearl New City. The event was hosted by the Guangzhou Branch of China Everbright Bank Co., Ltd., organized by Guangzhou Canton Biologics Technology Co., Ltd., and supported by the Guangzhou‑Hong Kong‑Macao High‑level Talent Achievement Transformation Promotion Association. The conference brought together representatives from government funds, financial institutions, biopharmaceutical companies, and research institutes to engage in in‑depth discussions on policy support for the biomedical industry in the Greater Bay Area (GBA), pathways for financial empowerment, and full‑chain biopharmaceutical services in the region.

Policy Leadership: The Greater Bay Area Goes All Out to Build a Biomedical Innovation Hub

As one of China’s core cities for the biomedical industry, Guangzhou continues to strengthen its policy support. On one hand, through the Guangzhou Station of the National Financing Credit Service Platform, it integrates government data, financial institution resources, and corporate credit information to provide precise financing services for biomedical enterprises. On the other hand, it promotes the upgrading of the biomedical industry chain via the “chain chief system”, using tax incentives, R&D subsidies, and talent attraction policies to accelerate the incubation of innovative drug companies and technology transfer, helping to build a hundred‑billion‑level biomedical industrial cluster in Guangzhou.

Financial Assistance: China Everbright Bank Provides Multi‑Dimensional Support for Biomedical Enterprise Financing

As the host, the Guangzhou Branch of China Everbright Bank has long been deeply involved in financial services for the biomedical sector. A branch representative noted at the conference that, in response to the asset‑heavy, long‑cycle, and high‑risk characteristics of biomedical enterprises, the bank has launched specialized financial products such as “R&D loans” and “patent pledge financing”, and has set up biomedical industry funds together with government and industrial investment institutions, covering the full lifecycle funding needs of enterprises from R&D to commercialization. In addition, through its “investment‑loan linkage” model, the bank has provided nearly RMB 5 billion in comprehensive credit support to more than 30 biomedical enterprises in the GBA, effectively alleviating current financing difficulties faced by innovative drug companies.

Industry Empowerment: Canton Biologics Demonstrates CDMO Leadership in the Greater Bay Area

As the earliest established and largest large‑molecule biopharmaceutical CDMO in the GBA, Guangzhou Canton Biologics drew significant attention at the event. Dr. Shen Xiao, CEO of Canton Biologics, stated that leveraging the policy dividends of the GBA and its own technical strengths, Canton Biologics can provide one‑stop CDMO services – from gene sequence optimization and cell line development to commercial production – to biopharmaceutical customers in the GBA and around the world. The company is now accelerating its expansion into cutting‑edge fields such as mRNA and ADC drugs. It has already served more than 200 well‑known domestic and international pharmaceutical companies, including BeiGene and HEC Pharma, helping biopharmaceutical companies improve R&D efficiency and shorten time‑to‑market for new drugs. Canton Biologics looks forward to establishing partnerships with more GBA biopharmaceutical companies through its CDMO platform, jointly enhancing the global competitiveness of China’s biopharmaceutical industry.

Relying on its self‑built platform spanning “gene sequence optimization – clinical sample production – commercial production”, the company has formed three core strengths:

1. End‑to‑end service capability: Canton Biologics offers integrated services including sequence optimization, cell line development, clinical and commercial sample production (15,000 L drug substance capacity), and formulation filling (four lines: pre‑filled syringes, vials, lyophilization, blow‑fill‑seal). Its service cycle is 30% faster than the industry average.

2. Cutting‑edge technology breakthroughs: The company has established technological barriers in bispecific antibodies and difficult‑to‑express proteins (e.g., IgM), having taken on 32 Class‑1 new drug projects.

3. Greater Bay Area geographical advantages: Proximity to six key biomedical universities such as the Hong Kong University of Science and Technology, and collaborations with institutions like the First Affiliated Hospital of Sun Yat‑sen University to build an “industry‑academia‑research‑application” ecosystem. In 2024, newly added local clients accounted for 67% of the total, helping GBA enterprises such as HEC Pharma and Zhaoke Bio achieve dual filing of innovative drugs in both China and the United States.

Cutting‑Edge Topics Spark New Industry Momentum

The conference agenda focused on hot industry topics, with multiple experts sharing innovative achievements:

• Global biopharmaceutical R&D landscape: Scholars noted that China’s innovative biologic drug market is expected to exceed RMB 1 trillion by 2030. Guangzhou, leveraging its concentration of clinical resources, is becoming the preferred location for multinational pharmaceutical companies to localize R&D.

• Breakthrough therapy explorations: For example, the “anti‑Aβ42 PD1 antibody platform” opens new paths for cancer treatment by targeting immunomodulatory molecules, and the “EB virus acute infection targeted drug” fills the gap in anti‑EB virus medications.

• Fintech integration: China Everbright Bank demonstrated its “biomedical big data risk control model”, which uses AI to assess technology value and improve financing efficiency.
  

Through policy interpretation, financial solution matching, and technical discussions, this conference built a collaborative innovation platform bringing together government, banks, and enterprises. With Guangzhou’s biomedical industry policies continuing to intensify, financial institutions providing precise support, and CDMO and other supporting services improving, the Greater Bay Area is accelerating its march toward becoming a new global hub for the bioeconomy.